title: A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
abstract: To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.
authors.affiliation: Medical College of Virginia/Virginia Commonwealth University, Richmond, VA 23298-0163, USA. SADLER@HSC.VCU.EDU
authors.forename: S P
authors.initials: SP
authors.lastname: Adler
authors.forename: S A
authors.initials: SA
authors.lastname: Plotkin
authors.forename: E
authors.initials: E
authors.lastname: Gonczol
authors.forename: M
authors.initials: M
authors.lastname: Cadoz
authors.forename: C
authors.initials: C
authors.lastname: Meric
authors.forename: J B
authors.initials: JB
authors.lastname: Wang
authors.forename: P
authors.initials: P
authors.lastname: Dellamonica
authors.forename: A M
authors.initials: AM
authors.lastname: Best
authors.forename: J
authors.initials: J
authors.lastname: Zahradnik
authors.forename: S
authors.initials: S
authors.lastname: Pincus
authors.forename: K
authors.initials: K
authors.lastname: Berencsi
authors.forename: W I
authors.initials: WI
authors.lastname: Cox
authors.forename: Z
authors.initials: Z
authors.lastname: Gyulai
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D018150:Avipoxvirus / Q000235:genetics / Q000276:immunology*; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000517:prevention & control; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008875:Middle Aged; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
chemical_list: C078788:ALVAC vaccine; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C040495:glycoprotein B, Simplexvirus